Skip to main content
OpenTrials
Completed

NCT Number: NCT03753464

The Role of Functional Epigenetic Modifications in Peri-Implantitis

The aim of this pilot, exploratory, single blind clinical trial is to evaluate the epigenetic changes associated with peri-implantitis.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Bluestone Center for Clinical Research. New York University College of Dentistry

New York, 10010-4086, United States

About this study

Twenty patients will be voluntarily enrolled in two groups: 10 healthy participants, and 10 participants with peri-implantitis. Periodontal and peri-implant clinical and radiographic measurements, as well as body mass index, medical and dental history will be recorded within the following timelines: at baseline (for both groups), and 6 months after baseline for the peri-implantitis group only. At baseline, gingival biopsies and blood will be harvested from: a) healthy gingival sites during either surgical removal of wisdom teeth or gingivoplasty, in the healthy group; and, b) from a peri-implantitis site during surgical treatment of peri-implantitis, and when possible, from a healthy gingival site within the same participant, in the peri-implantitis group. After harvesting of biopsies, peri-implantitis subjects will be re-evaluated 6 months after treatment. During the 6-month visit, if a second surgical treatment of peri-implantitis in the same implant treated at baseline is indicated as standard of care of the participant, a new gingiva biopsy and blood will be collected. Gingival biopsies and blood collected from each participant will be used to perform DNA methylation analysis.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

General Inclusion Criteria:

  • Subjects must have read, understood, and signed an informed consent form.
  • Subjects must be 20-90 years of age.
  • Subjects must be non-smokers or ex-smokers who have quit smoking for at least one year prior to enrollment in the study.
  • Subjects must be in good general health as assessed by the Investigator.

Healthy Periodontal Subjects Inclusion Criteria:

In addition to the general inclusion criteria, a healthy periodontal subject must meet all of the following criteria:

  • Subjects show gingival health and no history of periodontitis, as described in the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions.

Peri-implantitis Subjects Inclusion Criteria:

In addition to the general inclusion criteria, a PIT subject must meet all of the following criteria:

  • Subjects with implant-supported prosthesis/es in function for at least 12 months who had at least one implant diagnosed with peri-implantitis based on the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions.
  • Subjects must be committed to the study and the required follow-up visits.
  • Standard of care treatment of the diseased implant with PID will consist on open flap debridement (OFD).

Exclusion criteria

General Exclusion Criteria:

  • Pregnant or lactating.
  • Use of antibiotics, within 1 month before enrollment in the study.
  • Chronic use of nonsteroidal anti-inflammatory drugs for over 3 weeks of continuous use at the time of enrollment or during the course of the study.
  • Requirement for prophylactic antibiotics for dental procedures.
  • Mucosal diseases in the localized area around the biopsy site.
  • Subjects with a systemic disease that would preclude biopsy/oral surgery.
  • History of local irradiation therapy in the head/neck area.
  • Subjects with poor oral hygiene.
  • Subjects receiving, or having a history of receiving intravenous or subcutaneous anti-resorptive agents associated with osteonecrosis of the jaw.
  • Subjects with any untreated endodontic lesions or untreated periodontal disease adjacent to the biopsy site.
  • Acute necrotizing ulcerative gingivitis or gross tooth decay, as determined by the investigator.
  • Subjects with conditions or circumstances, in the opinion of the investigator, which would prevent completion of study participation or interfere with analysis.

Periodontally Healthy Subjects Exclusion:

In addition to the general exclusion criteria, subjects allocated to the healthy group who meet any of the following criteria will be excluded from participation in this study:

  • Root fragments, pericoronitis, endo-perio lesions, gross tooth decay, or other dental abscesses at the biopsy site. Subjects may be rescreened after resolution of these dental conditions.

Peri-implantitis subjects Exclusion:

In addition to the general exclusion criteria, subjects allocated to the PIT group who meet any of the following criteria will be excluded from participation in this study:

  • Inadequate implant position (i.e., prosthetically driven).
  • PIT due to excess of cement.
  • Subjects who have physical or mental handicaps that would interfere with the ability to perform adequate oral hygiene.
  • Subjects with implants previously surgically treated for PIT.
  • Less than 2mm of keratinized peri-implant tissue.

Treatment and study plan

Gingival biopsy and blood sample collection

Procedure

Gingival and blood samples will be collected.

Primary outcomes

  1. Differences in epigenetic signatures in peri-implantitis subjects as compared to healthy subjects, in an exploratory manner. (Gingival biopsies and blood collected to perform DNA methylation analysis)

    Time frame: 6 months

    Gingival and blood samples collected from healthy subjects and subjects with peri-implantitis will be used to determinate epigenetic signatures associated with peri-implantitis.

  2. Epigenetic signatures associated with response to treatment peri-implantitis at 6 months, in an exploratory manner. (Differences in epigenetic signatures in peri-implantitis subjects as compared to healthy subjects, in an exploratory manner.

    Time frame: 6 months

    Samples collected from patients with peri-implantitis will be used to determinate epigenetic signatures associated response to treatment peri-implantitis at 6 months. (Gingival biopsies and blood collected to perform DNA methylation analysis)

Secondary outcomes

  1. Visual Analog Scale (VAS) will be assessed to determinate patient-reported outcome measures, at baseline and at 6 months.

    Time frame: 6 months

    A visual analog scale (VAS) will be used to evaluate patient's pain/discomfort, esthetic satisfaction, and the subjects' overall satisfaction at baseline and at 6 months.

  2. Oral Health Impact Profile-14 (OHIP-14) will be assessed to determinate patient-reported outcome measures, at baseline and at 6 months.

    Time frame: 6 months

    Oral Health Impact Profile-14 (OHIP-14) assessed at baseline and at 6 months.

  3. Changes in peri-implant pocket depths (PPD) (in mm) from baseline to 6 month after surgery (only peri-implantitis group).

    Time frame: 6 months

    Peri-implant pocket depths (PPD) will be assessed at baseline and 6 month after surgery.

  4. Changes in peri-implant BOP (in percentage), from baseline to 6 month after surgery (only peri-implantitis group).

    Time frame: 6 months

    Peri-implant BOP (in percentage) will be assessed at baseline and 6 month after surgery.

  5. Percentage of peri-implant pocket closure at to 6 month after surgery (only peri-implantitis group).

    Time frame: 6 months

    Percentage of peri-implant pocket closure will be assessed at at to 6 month after surgery.

  6. Changes in peri-implant marginal bone level (in mm) from baseline to 6 month after surgery (only peri-implantitis group).

    Time frame: 6 months

    Mean crestal bone level change around the implants will be determined by periapical radiographs of mesial and distal bone levels from baseline to 6 months surgery.

  7. Change in soft tissue levels (in mm) from baseline to 6 month after surgery (only peri-implantitis group).

    Time frame: 6 months

    Soft tissue levels assessed at baseline and 6 months post-surgery in implants with peri-implantitis.

  8. Incidence of post-operative surgical site infections (only peri-implantitis group).

    Time frame: 6 months

    Number of post-operative surgical site infections from surgery to 6 months.

  9. Incidence of post-operative complications (only peri-implantitis group).

    Time frame: 6 months

    Number of post-operative complications from surgery to 6 months.

Sponsors and collaborators

Lead sponsor

NYU College of Dentistry

Other

Registry information

Official study title

The Role of Functional Epigenetic Modifications in Peri-Implantitis: A Pilot Clinical Study

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Nov 27, 2018
Registry last updated
Jul 3, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.